Loading...

Custom Cancer Insurance And Digital Underwriting Will Drive Future Expansion

Published
06 Aug 24
Updated
04 Oct 25
AnalystConsensusTarget's Fair Value
US$108.31
2.6% overvalued intrinsic discount
04 Oct
US$111.17
Loading
1Y
-0.4%
7D
0.5%

Author's Valuation

US$108.312.6% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update04 Oct 25
Fair value Increased 0.21%

Aflac's analyst price target has been raised slightly, with an increase of $2 to $108. Analysts highlight strong Q2 sales driven by new product rollouts and improved net interest income.

Analyst Commentary

Following the release of Aflac's second quarter results, analysts have reacted by adjusting price targets upward, reflecting recent business momentum and updated financial expectations. The analyst community offered both encouraging observations and areas for caution based on the company's current performance and forward-looking prospects.

Bullish Takeaways
  • Bullish analysts raised price targets, expressing confidence in Aflac's sales rebound, particularly driven by the successful launch of the new cancer product.
  • Improved net interest income and strong revenue from the company's Japanese operations contributed to upward earnings per share revisions for the second half of the year.
  • Upbeat quarterly results have prompted analysts to update and enhance their financial models, reflecting better-than-expected operational execution.
  • The company's ability to capitalize on product innovation and drive growth in key markets was a noted factor in improving overall sentiment around valuation.
Bearish Takeaways
  • Bearish analysts remain cautious about the sustainability of new cancer product sales, noting that current momentum may wane after the initial uptake from the existing customer base.
  • Some price targets, despite being raised, coincide with maintained neutral or underperform ratings, suggesting ongoing uncertainty about sustaining recent growth trends.
  • The outlook for future quarters hinges on Aflac's execution and ability to drive incremental growth beyond one-time effects from new product launches.

What's in the News

  • On August 12, 2025, Aflac announced it is increasing its equity buyback plan authorization by 100,000,000 shares, bringing the total authorization to 380,000,000 shares (company filing).
  • Between April 1 and June 30, 2025, Aflac repurchased 7,915,802 shares for $829.2 million. This completes the repurchase of 249,095,785 shares totaling $15,867.46 million under the buyback plan initially announced in 2017 (company filing).

Valuation Changes

  • Fair Value Estimate has increased slightly, now at $108.31 from $108.08.
  • Discount Rate has declined marginally, moving from 6.83% to 6.79%.
  • Revenue Growth projection is up very slightly, at 5.11% compared to 5.10% previously.
  • Net Profit Margin estimate is nearly unchanged, showing a small decrease from 20.40% to 20.39%.
  • Future P/E Ratio expectation has edged up, rising to 16.70x from 16.68x.

Key Takeaways

  • Product innovation and digitalization expand Aflac's market reach, support topline growth, and improve operational efficiency and customer engagement.
  • Investment portfolio diversification and new distribution strategies enhance earnings stability and drive sustained long-term income growth.
  • Heavy reliance on Japan and challenging investment returns, along with weak U.S. sales growth, pose ongoing risks to Aflac's revenue, earnings, and margin stability.

Catalysts

About Aflac
    Through its subsidiaries, provides supplemental health and life insurance products.
What are the underlying business or industry changes driving this perspective?
  • The successful launch of new, customizable cancer insurance (Miraito) in Japan, coupled with strong early sales across all distribution channels-including banks and Japan Post-positions Aflac to capture growing demand for supplemental health coverage among aging and younger consumers, supporting topline revenue and premium growth.
  • Increased adoption of digital underwriting, customer-facing Gen AI, and digital human avatar initiatives in both Japan and the U.S. is expected to lower long-term operational costs and improve customer engagement, with the potential to materially expand net margins through enhanced efficiency and better scalability.
  • Heightened consumer awareness of financial health risks and rising medical costs-combined with product innovation (such as modular coverage, new children's cancer policies, and expanded group dental/vision)-broadens Aflac's addressable market and increases cross-sell opportunities, supporting both revenue and persistency.
  • Ongoing diversification and optimization of Aflac's investment portfolio, including the proactive management of yen
  • and USD-denominated assets, positions the company to better withstand interest rate cycles and enhance investment income stability, reducing earnings volatility and supporting sustainable bottom-line growth.
  • Strategic expansion in digital direct-to-consumer channels in the U.S., aggressive agent recruitment in Japan, and new partnerships with large institutions (like state-run disability leave programs) enable Aflac to extend market reach and drive sustained earned premium and fee-based income growth over the long term.

Aflac Earnings and Revenue Growth

Aflac Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming Aflac's revenue will grow by 5.1% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 15.3% today to 20.4% in 3 years time.
  • Analysts expect earnings to reach $3.8 billion (and earnings per share of $7.92) by about September 2028, up from $2.4 billion today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 16.7x on those 2028 earnings, down from 23.3x today. This future PE is greater than the current PE for the US Insurance industry at 14.3x.
  • Analysts expect the number of shares outstanding to decline by 3.73% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 6.83%, as per the Simply Wall St company report.

Aflac Future Earnings Per Share Growth

Aflac Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  •  Net earned premiums in Japan, Aflac's largest and most profitable market, continued to decline year-over-year (down 1.1% excluding one-off effects), and management's guidance recognizes ongoing negative premium growth of -1% to -2% for the foreseeable future, which could constrain future revenue and earnings growth.
  •  The company is experiencing increased technology and expense ratios in Japan (up 280 basis points year-over-year), largely due to digital transformation initiatives; if these investments do not translate into commensurate productivity gains, net margins may remain under pressure.
  •  Aflac's significant exposure to Japan subjects it to persistent currency fluctuations and economic uncertainty-yen depreciation directly impacts reported USD earnings and the efficacy of capital deployment (including 65% of debt held in yen), increasing volatility in both reported revenue and earnings per share.
  •  Variable net investment income was materially below long-term targets in the quarter (down 10.5% in yen terms for Japan), highlighting the ongoing risk from persistent low global bond yields and challenging investment environments, which could lead to lower investment returns and net margins over the long-term.
  •  Persistent sluggishness in U.S. sales (only a 2.7% year-over-year increase), still not at historical growth rates, and dependence on agent recruitment and effectiveness in the traditional distribution channel, points to execution risk; failure to reinvigorate U.S. sales growth may limit future revenue expansion and earnings diversification.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of $108.077 for Aflac based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $124.0, and the most bearish reporting a price target of just $99.0.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $18.5 billion, earnings will come to $3.8 billion, and it would be trading on a PE ratio of 16.7x, assuming you use a discount rate of 6.8%.
  • Given the current share price of $106.28, the analyst price target of $108.08 is 1.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives